We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





New Test Developed Using AI Proves Almost 100% Accurate in Detecting  COVID-19 Antibodies

By LabMedica International staff writers
Posted on 13 Dec 2021
Print article
Illustration
Illustration

A new test developed using AI-assisted technology has proven to be almost 100% accurate in detecting COVID antibodies.  

The Universal EpitoGen SARS-Cov-2-test developed by scientists at the University of Aberdeen (Aberdeen, Scotland) passed the penultimate round of quality assurance assessments by the NIBSC with a reported accuracy that would outperform existing COVID tests. In the NIBSC assessment, the Universal EpitoGen test detected antibody responses to infection by SARS-CoV-2 virus from patient samples with more than 99.5% accuracy and 98.5% specificity.

Unlike the ‘traditional,’ currently used tests, that can become less accurate as new variants emerge, the innovative EpitoGen technology is just as effective in detecting an antibody response to new variants without losing accuracy. Therefore, the new tests can be used to estimate the prevalence of circulating variant strains in the community, including the Omicron variant.

The Universal EpitoGen test was developed using innovative AI antibody technology known as EpitoGen and is one of a suite of tests currently in development. These include tests that can also assess the effectiveness of vaccines against new mutations and allows the incorporation of new mutations into existing tests in a matter of days - something that is not possible using the current technology.

“The news that our tests are so remarkably accurate is extremely exciting, particularly given the increasing worry around the emergence of new variants,” said Professor Mirela Delibegovic from the University of Aberdeen and academic lead on the project. “These tests can be adapted quickly and efficiently to incorporate new mutations - an important development, as we are right now realizing the importance of detecting and monitoring new COVID variants. So, to have the validation that this test has such a phenomenal level of accuracy is hugely encouraging and important.”

Related Links:
University of Aberdeen 

New
Gold Member
Multiplex Genetic Analyzer
MassARRAY Dx Analyzer (Europe only)
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Herpes Simplex Virus ELISA
HSV 2 IgG – ELISA
New
PSA Test
Humasis PSA Card

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.